Review |
From the Divisions of Cardiovascular Research and Vascular Medicine, St. Elizabeths Medical Center, and the Program in Cell, Molecular and Developmental Biology, Sackler School of Biomedical Studies, Tufts University School of Medicine, Boston, Mass.
Correspondence to Dr Kenneth Walsh, Division of Cardiovascular Research, St. Elizabeths Medical Center, 736 Cambridge St, Boston, MA 02135. E-mail kwalsh@world.std.com or kwalsh{at}opal.tufts.edu
Key Words: remodeling atherosclerosis restenosis apoptosis
| Introduction |
|---|
|
|
|---|
Vascular Cell Apoptosis in Remodeling, Restenosis, and Plaque Rupture
Apoptosis During Cardiovascular Development Myocyte Apoptosis in Ischemic Heart Disease Endothelial Cell Apoptosis in Angiogenesis and Vessel RegressionRichard Kitsis, Guest Editor
Apoptotic death of vascular cells is a prominent feature of blood vessel remodeling that occurs during normal development and fibroproliferative disorders of the vessel wall. This review summarizes a large number of studies that have provided evidence for apoptotic cell death in the vasculature. We also describe reports that shed light on the molecular mechanisms that may control this process. Finally, we highlight the relatively small number of studies that suggest a function for vascular cell apoptosis in controlling the morphology and cellular composition of the blood vessel wall.
| Vascular Cell Apoptosis During Development and Flow-Induced Vessel Remodeling |
|---|
|
|
|---|
Vascular cell apoptosis during neonatal vascular remodeling appears to be triggered by decreased flow or by perturbation of flow at branch points that results when the organism switches oxygen exchange from the placenta to the lungs. Cell loss occurring upon flow-induced vessel remodeling has been directly demonstrated by inducing changes in flow through the carotid arteries of immature rabbits.4 In that experimental system, ligation of the left external carotid artery results in a marked reduction in blood flow through the common carotid artery, and this reduction correlates with a large increase in endothelial cell and VSMC apoptosis. Presumably, vascular cell apoptosis contributes to an adaptive process that allows the vessel to permanently constrict to manage the decrease in flow.
Changes in flow affect wall tension and cell matrix interactions, and it may be these factors that alter the survival characteristics of vascular cells. Consistent with this notion, VSMC apoptosis occurs when wall tension is diminished,5 or enhanced,6 or when the expression of matrix components7 or matrix metalloproteinases8 is altered. Although changes in the proapoptotic proteins Bax and Bcl-XS are associated with flow-induced vascular remodeling,2 relatively little is known about the molecular mechanisms that regulate vascular cell viability under these circumstances. Furthermore, although it makes intuitive sense that cellular elimination would be required for negative remodeling of a vessel, causal data in support of this hypothesis have not yet been provided.
| Apoptosis in Chronic Vascular Lesions |
|---|
|
|
|---|
The diminished plaque cellularity of advanced lesions may be attributed to VSMC apoptosis, and it has been proposed that VSMC apoptosis eventually contributes to plaque rupture. This stems from the observation that VSMCs cultured from atherosclerotic coronary atherectomy specimens proliferate more slowly and demonstrate higher frequencies of apoptosis than VSMCs from normal vessels.9 19 This process may lead to plaque destabilization since apoptotic and necrotic cells have been detected in atherosclerotic plaques with a recent history of rupture20 and VSMC apoptosis can be observed in the fibrous cap and underlying media of nonulcerated lesions obtained from human thoracic aorta and coronary arteries.13 However, causal data that could shed light on the relative importance of apoptotic cell death in plaque rupture have not been provided. Furthermore, the molecular mechanisms regulating cellular viability in chronic vascular lesions have not been defined in detail.
| Vascular Cell Apoptosis Induced by Acute Balloon Injury |
|---|
|
|
|---|
1 hour
after injury but is no longer evident by 4 hours after injury. The
frequency of apoptotic cells correlates with the decrease in
cellular density (up to 65%) that is observed within hours of injury.
This rapid decrease in vessel wall cellularity occurs before the
initiation of cell-cycle activity in VSMCs.22 Although the
consequences of early-onset apoptosis in medial VSMCs are
unknown, it could exacerbate neointima lesion formation at
later time points by provoking a greater wound healing response to
overcome the cellular deficit. Consistent with this notion,
cells can release cytokines as they undergo
apoptosis,23 and this could enhance the
proliferative response after traumatic balloon injury. The second wave of apoptosis occurs at much later times after injury (days to weeks) and at much lower frequencies. In the rat carotid model, apoptosis at these later time points is confined to the VSMCs of the developing neointima.24 25 This second wave of apoptosis may limit lesion growth. It has long been known that VSMC accumulation in the neointima of injured rat carotid arteries reaches a maximal level at 2 weeks after injury, yet cellular proliferation continues for up to 12 weeks.26 Presumably the rates of neointimal VSMC death and proliferation are in equilibrium from 2 weeks onward, thereby preventing any further increase in lesion size.
Rapid balloon angioplastyinduced apoptosis has also been documented in the rabbit iliac model.21 In this case, increased balloon-to-artery ratios produce greater frequencies of VSMC apoptosis at early time points, and this correlates with more acute cell loss.27 The rapid wave of apoptosis resulting from mechanical injury appears to involve a redox-sensitive pathway, because local administration of antioxidants will minimize cell loss.28 Surprisingly, analyses of diseased vessels have revealed that VSMCs of the neointima are less sensitive to rapid-onset apoptosis than are the VSMCs of the underlying media,27 29 suggesting that modulation of the VSMC phenotype influences angioplasty-induced apoptosis. Normocholesterolemic and hypercholesterolemic rabbits display similar profiles of early postinjury apoptosis, but hypercholesterolemia enhances apoptosis in the neointima at 2 weeks after injury.30 This observation has led to the hypothesis that macrophages present in the vascular lesions of the hypercholesterolemic rabbits may contribute to VSMC turnover at later time points. Macrophage involvement has also been implicated in VSMC apoptosis observed after stent implantation in rabbit vessels.31
Finally, VSMC apoptosis has also been described in balloon-injured porcine coronary arteries.32 In this model, apoptosis is first observed at sites of obvious trauma at 1 hour after injury and, at later times, in the deeper layers of the media. Medial VSMC apoptosis peaks at 18 hours after injury, and lower levels of apoptosis are observed at 3 days and 7 days, but not at 14 days. The time course of apoptosis in cells of the adventitia and loose connective tissue was similar to that of medial cells.
| Regulation of Vascular Cell Viability by Bcl-2 Family Proteins |
|---|
|
|
|---|
The functional significance of Bcl-2 family proteins in VSMC survival has been demonstrated by acute ablation experiments. It has been shown that neointimal VSMC apoptosis can be induced in stenotic vessels by Bcl-XL ablation using an antisense strategy, leading to a reduction in intimal thickness.29 Because Bcl-XL is preferentially expressed in neointimal VSMCs, this factor may contribute to the differential sensitivity of medial and neointimal VSMCs to balloon injuryinduced apoptosis. VSMC apoptosis can also be triggered by acute ablation of Bcl-2 using an adenovirus-encoded ribozyme directed against bcl-2 mRNA, which brings about a decrease in vessel wall cellularity and reduced intimal lesion formation after balloon injury.33 Collectively, these studies show that endogenous levels of Bcl-2 and Bcl-XL are essential for VSMC viability, and thus, stimuli that alter Bcl-XL or Bcl-2 expression could influence VSMC survival in the vessel wall.
In addition to the Bcl-2 family proteins, it has been suggested that the transcription factor p53 regulates vascular cell apoptosis because p53 is reported to accumulate in atherosclerotic lesions.34 This factor promotes apoptosis by functioning, at least in part, as a positive regulator of Bax expression35 and a negative regulator of Bcl-2 expression.36 Interestingly, p53 can also promote VSMC apoptosis by increasing cell surface expression of the death ligand receptor Fas.37 Forced overexpression of p53 induces VSMC apoptosis in vitro and inhibits neointima lesion formation in vivo.19 38 In addition to this proapoptotic function, p53 negatively regulates cell growth through its ability to induce the cyclin-dependent kinase inhibitor p21.39 Consistent with expectations from in vitro studies, p53 deficiency exacerbates atherosclerotic lesion expansion in ApoE-deficient mice fed a high-fat diet40 However, this lack of p53 has no effect on the frequency of vascular cell apoptosis within the lesions; the increase in lesion size appears to result from increased vascular cell proliferation. As a consequence of these observations, the role of p53 in controlling cell death within atherosclerotic lesions is uncertain.
| Death Receptor/Ligand Interactions in Vascular Cells |
|---|
|
|
|---|
It has been proposed that Fas-mediated apoptosis
plays a role in a variety of vascular disorders including
atherogenesis,51 52 53 54 55 allograft
arteriopathy,56 and acute inflammatory
responses.49 Because VSMCs express Fas and inflammatory
cells express FasL, it is possible that Fas-mediated apoptosis
contributes to atherosclerotic plaque instability.54 The
susceptibility of VSMCs to Fas-mediated cell death in vitro and in vivo
has been documented in numerous studies. Cultured VSMCs undergo
apoptosis after infection with a replication-defective
adenoviral vector that encodes cell surface FasL.50 57
Consistent with its expression on the cell surface, coculture
experiments reveal that FasL-expressing VSMCs kill cells in a paracrine
manner. Local delivery of adenovirus encoding FasL to balloon-injured
rat carotid arteries induces apoptosis in proliferating smooth
muscle cells and potently inhibits intimal hyperplasia.57
Although VSMCs are susceptible to adenovirus-encoded FasL expressed at
the cell surface, they are not efficiently killed by soluble
recombinant FasL or agonist antiFas antibody.50
Presumably these soluble reagents are less efficient than cell surface
FasL at inducing Fas clustering on the membrane of the target
cell.58 Consistent with this interpretation, VSMCs
are sensitized to Fas-mediated apoptosis by interferon
,
which favors receptor clustering by upregulating cell surface Fas
expression.50 54 59
In striking contrast to VSMCs, vascular
endothelial cells are normally resistant to
Fas-mediated apoptosis51 60 and remain
resistant even when Fas expression is upregulated by exposure
to interferon
,50 60 suggesting that resistance is not
due to low levels of receptor expression. The marked differences in the
sensitivity of vascular cells to Fas-induced apoptosis may be
mediated by the expression of cellular FLIPs (FLICE-like
inhibitory proteins) that function as dominant-negative
inhibitors of caspase-8 function.61 62 FLIP
isoforms are abundantly expressed in endothelial cells
where they may function to inhibit Fas-mediated cell suicide (or
fratricide).63 Along these lines, it is reported that FLIP
expression in rat carotid VSMCs is downregulated after balloon injury
and human atherosclerotic plaque VSMCs express relatively low levels of
FLIP,64 suggesting that FLIP may participate in the
regulation of VSMC turnover in those lesions.
Many lines of evidence suggest that Fas-mediated cell death is
important in the control of vessel wall inflammation. First, it has
been shown that a deficiency in Fas-mediated apoptosis will lead to
vasculitis, resulting from neutrophilic and mononuclear cell
infiltrates, in some strains of gld and lpr
mice.65 66 Second, FasL-deficient mice display
enhanced mononuclear cell infiltration and intimal hyperplasia in a
flow-restricted model of vascular injury that induces
neointima formation in the presence of an intact
endothelium.67 Third, it has been shown
that constitutive overexpression of FasL on the vascular
endothelium will inhibit tumor necrosis
factor-
mediated leukocyte extravasation.49 Also,
consistent with an anti-inflammatory role, ectopic FasL
expression by medial VSMCs in balloon-injured arteries inhibits T
cellmediated inflammatory responses directed against
adenovirus-infected cells.57 68 Because chronic vessel
inflammation is an important component of atherogenesis, FasL may serve
an atheroprotective function through its ability to kill inflammatory
cells. Alternatively, dysregulated expression of the Fas signaling
pathway could, under some conditions, promote
atherosclerosis. For example, oxidized lipids and other
oxidative stresses can sensitize endothelial cells to
Fas-mediated apoptosis by downregulating FLIP
expression.51 63 Thus, Fas-mediated apoptosis of
endothelial cells may contribute to a loss of
endothelium integrity in diseased vessels.
Collectively, data from mouse and other experimental systems largely support the hypothesis that Fas inhibits vascular inflammation and serves a protective role during vascular remodeling; however, causal data linking Fas-mediated apoptosis to atherogenesis and plaque rupture have not appeared to date.
| Closing Remarks |
|---|
|
|
|---|
With regard to molecular control of apoptosis and vascular cell viability, the following may be said:
In conclusion, the data suggesting that apoptosis plays a role in developmentally regulated or pathological vessel remodeling are largely correlative. In this regard, further definition of regulatory pathways and directed gene ablation studies would be helpful in defining the respective roles of these factors in controlling vessel architecture in development and disease.
| Acknowledgments |
|---|
Received April 14, 2000; accepted June 12, 2000.
| References |
|---|
|
|
|---|
2.
Kim HS, Hwang KK, Seo JW, Kim SY, Oh BH, Lee MM,
Park YB. Apoptosis and regulation of Bax and Bcl-X proteins
during human neonatal vascular remodeling. Arterioscler Thromb
Vasc Biol. 2000;20:957963.
3.
Cho A, Courtman DW, Langille BL.
Apoptosis (programmed cell death) in arteries of the neonatal
lamb. Circ Res. 1995;76:168175.
4.
Cho A, Mitchell L, Koopmans D, Langille BL.
Effects of changes in blood flow rate on cell death and cell
proliferation in carotid arteries of immature rabbits. Circ
Res. 1997;81:328337.
5.
Bayer IM, Adamson SL, Langille BL. Atrophic
remodeling of the artery-cuffed artery. Arterioscler Thromb Vasc
Biol. 1999;19:14991505.
6.
Lauth M, Berger MM, Cattaruzza M, Hecker M.
Elevated perfusion pressure upregulates endothelin-1 and endothelin B
receptor expression in the rabbit carotid artery.
Hypertension. 2000;35:648654.
7.
Jones PL, Crack J, Rabinovitch M.
Regulation of tenascin-C, a vascular smooth muscle cell survival factor
that interacts with the
vß3 integrin to
promote epidermal growth factor receptor
phosphorylation and growth. J Cell
Biol. 1997;139:279293.
8. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998;101:14781487.[Medline] [Order article via Infotrieve]
9. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:22662274.
10. Geng JY, Libby P. Evidence for apoptosis in advanced human atheroma: colocalization with interleukin-1ß converting enzyme. Am J Pathol. 1995;147:251266.[Abstract]
11.
Isner JM, Kearney M, Bortman S, Passeri J.
Apoptosis in human atherosclerosis and
restenosis. Circulation. 1995;91:27032711.
12.
Mallat Z, Ohan J, Leseche G, Tedugi A.
Colocalization of CPP-32 with apoptotic cells in human
atherosclerotic plaques. Circulation. 1997;96:424428.
13. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol. 1996;149:367380.[Abstract]
14.
Kockx MM, De Meyer GR, Muhring J, Jacob W, Bult
H, Herman AG. Apoptosis and related proteins in different
stages of human atherosclerotic plaques. Circulation. 1998;97:23072315.
15.
Kearney M, Pieczek A, Haley L, Losordo DW,
Andrés V, Schainfeld R, Rosenfield K, Isner JM. Histopathology of
in-stent restenosis in patients with peripheral
artery disease. Circulation. 1997;95:19982002.
16. Kockx MM, DeMeyer GRY, Muhring J, Bult H, Bultinck J, Herman AG. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis. 1996;120:115124.[Medline] [Order article via Infotrieve]
17.
Lutgens E, Daemen M, Kockx M, Doevendans P,
Hofker M, Havekes I, Wellens H, de Muinck ED.
Atherosclerosis in APOE*3-Leiden transgenic mice: from
proliferative to atheromatous stage.
Circulation. 1999;99:276283.
18. Harada K, Chen Z, Ishibashi S, Osuga J, Yagyu H, Ohashi K, Yahagi N, Shionoiri F, Sun L, Yazaki Y, Yamada N. Apoptotic cell death in atherosclerotic plaques of hyperlipidemic knockout mice. Atherosclerosis. 1997;135:235239.[Medline] [Order article via Infotrieve]
19.
Bennett MR, Macdonald K, Chan SW, Boyle JJ,
Weissberg PL. Cooperative interactions between RB and p53 regulate cell
proliferation, cell senescence, and apoptosis in human vascular
smooth muscle cells from atherosclerotic plaques. Circ Res. 1998;82:704712.
20. Crisby M, Kallin B, Thyberg J, Zhivotovsky B, Orrenius S, Kostulas V, Nilsson J. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis. 1997;130:1727.[Medline] [Order article via Infotrieve]
21.
Perlman H, Maillard L, Krasinski K, Walsh K.
Evidence for the rapid onset of apoptosis in medial smooth
muscle cells following balloon injury. Circulation. 1997;95:981987.
22. Wei GL, Krasinski K, Kearney M, Isner JM, Walsh K, Andrés V. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ Res. 1997;80:418426.
23. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T. Caspase 1-independent IL-1ß release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med. 1998;4:12871292.[Medline] [Order article via Infotrieve]
24. Bochaton-Piallat M, Gabbiani F, Redard M, Desmouliere A, Gabbiani G. Apoptosis participates in cellularity regulation during rat aortic intimal thickening. Am J Pathol. 1995;146:10591064.[Abstract]
25. Han DKM, Haudenschild CC, Hong MK, Tinkle BT, Leon MB, Liau G. Evidence for apoptosis in human atherogenesis and in a rat vascular injury model. Am J Pathol. 1995;147:267277.[Abstract]
26. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury, I: smooth muscle cell growth in the absence of endothelium. Lab Invest. 1983;49:327333.[Medline] [Order article via Infotrieve]
27. Rivard A, Luo Z, Perlman H, Fabre JE, Nguyen T, Maillard L, Walsh K. Early cell loss after angioplasty results in a disproportionate decrease in percutaneous gene transfer to the vessel wall. Hum Gene Ther. 1999;10:711721.[Medline] [Order article via Infotrieve]
28.
Pollman MJ, Hall JL, Gibbons GH. Determinants of
vascular smooth muscle cell apoptosis after balloon angioplasty
injury. Circ Res. 1999;84:113121.
29. Pollman MJ, Hall ZL, Mann MJ, Zhang L, Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med. 1998;4:222227.[Medline] [Order article via Infotrieve]
30. Song JM, Kim HS, Rhee MY, Chae IH, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS, Lee YW. Effect of hypercholesterolemia on the sequential changes of apoptosis and proliferation after balloon injury to rabbit iliac artery. Atherosclerosis. 2000;150:309320.[Medline] [Order article via Infotrieve]
31. Kollum M, Kaiser S, Kinscherf R, Metz J, Kubler W, Hehrlein C. Apoptosis after stent implantation compared with balloon angioplasty in rabbits. Role of macrophages. Arterioscler Thromb Vasc Biol. 1997;17:23822388.
32.
Malik N, Francis SE, Holt CM, Gunn J, Thomas
GL, Shepherd L, Chamberlain J, Newman CMH, Cumberland DC, Crossman DC.
Apoptosis and cell proliferation after porcine coronary
angioplasty. Circulation. 1998;98:16571665.
33.
Perlman H, Sata M, Krasinski K, Dorai T, Buttyan
R, Walsh K. Adenovirus-encoded hammerhead ribozyme to Bcl-2 inhibits
neointimal hyperplasia and induces smooth muscle cell
apoptosis. Cardiovasc Res. 2000;45:570578.
34. Ihling C, Haendeler J, Menzel G, Hess RD, Fraedrich G, Schaefer HE, Zeiher AM. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol. 1998;185:303312.[Medline] [Order article via Infotrieve]
35. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293299.[Medline] [Order article via Infotrieve]
36.
Miyashita T, Harigal M, Hanada M, Reed JC.
Identification of a p53-dependent negative response element in the
bcl-2 gene. Cancer Res. 1994;54:31313135.
37.
Bennett M, Macdonald K, Chan SW, Luzio JP, Simari
R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of
p53-mediated apoptosis. Science. 1998;282:290293.
38.
Yonemitsu Y, Kaneda Y, Tanaka S, Nakashima Y,
Komori K, Sugimachi K, Sueishi K. Transfer of wild-type p53 gene
effectively inhibits vascular smooth muscle cell proliferation in vitro
and in vivo. Circ Res. 1998;82:147156.
39. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817825.[Medline] [Order article via Infotrieve]
40. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med. 1999;5:335339.[Medline] [Order article via Infotrieve]
41. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969976.[Medline] [Order article via Infotrieve]
42. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314317.[Medline] [Order article via Infotrieve]
43.
Nagata S, Golstein P. The Fas death factor.
Science. 1995;267:14491456.
44.
Kiener PA, Davis PM, Starling GC, Mehlin C,
Klebanoff SJ, Ledbetter JA, Liles WC. Differential induction of
apoptosis by Fas-Fas ligand interactions in human monocytes and
macrophages. J Exp Med. 1997;185:15111516.
45. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol. 1997;159:15941598.[Abstract]
46.
Perlman H, Pagliari LJ, Georganas C, Mano T,
Walsh K, Pope RM. FLICE-inhibitory protein expression
during macrophage differentiation confers resistance to
Fas-mediated apoptosis. J Exp Med. 1999;190:16791688.
47.
Griffith TS, Brunner T, Fletcher SM, Green DR,
Ferguson TA. Fas ligand-induced apoptosis as a mechanism of
immune privilege. Science. 1995;270:11891192.
48. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role of CD95 ligand in preventing graft rejection. Nature. 1995;377:630632.[Medline] [Order article via Infotrieve]
49.
Sata M, Walsh K. TNF
regulation of Fas
ligand expression on the vascular endothelium modulates
leukocyte extravasation. Nat Med. 1998;4:415420.[Medline]
[Order article via Infotrieve]
50.
Sata M, Suhara T, Walsh K. Vascular
endothelial cells and smooth muscle cells differ in
their expression of Fas and Fas ligand and in their sensitivity to Fas
ligand-induced cell death: implications for vascular disease and
therapy. Arterioscler Thromb Vasc Biol. 2000;20:309316.
51. Sata M, Walsh K. Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest. 1998;102:16821689.[Medline] [Order article via Infotrieve]
52. Fukuo K, Nakahashi T, Nomura S, Hata S, Suhara T, Shimizu M, Tamatani M, Morimoto S, Kitamura Y, Ogihara T. Possible participation of Fas-mediated apoptosis in the mechanism of atherosclerosis. Gerontology. 1997;43:3542.
53. Cai W, Devaux B, Schaper W, Schaper J. The role of Fas/APO 1 and apoptosis in the development of human atherosclerotic lesions. Atherosclerosis. 1997;131:177186.[Medline] [Order article via Infotrieve]
54.
Geng Y-J, Henderson LE, Levesque EB, Muszynzki M,
Libby P. Fas is expressed in human atherosclerotic intima and promotes
apoptosis of cytokine-primed human vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:22002208.
55.
Schneider DB, Vassalli G, Wen S, Driscoll RM,
Sassani AB, DeYoung MB, Linnemann R, Virmani R, Dichek DA. Expression
of Fas ligand in arteries of hypercholesterolemic
rabbits accelerates atherosclerotic lesion formation.
Arterioscler Thromb Vasc Biol. 2000;20:298308.
56. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest. 1996;74:921931.[Medline] [Order article via Infotrieve]
57.
Sata M, Perlman H, Muruve DA, Silver M, Ikebe M,
Libermann TA, Oettgen P, Walsh K. Fas ligand gene transfer to the
vessel wall inhibits neointima formation and overrides the
adenovirus-mediated T cell response. Proc Natl Acad Sci
U S A. 1998;95:12131217.
58. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4:3136.[Medline] [Order article via Infotrieve]
59. Fukuo K, Suhara T, Nakahashi T, Hata S, Shimizu M, Niinobu T, Morimoto S, Ogihara T. Activated T cells induce up-regulation of Fas antigen in cultured endothelial cells. Heart Vessels. 1997;suppl 12:8183.
60. Richardson BC, Lalwani ND, Johnson KJ, Marks RM. Fas ligation triggers apoptosis in macrophages but not endothelial cells. Eur J Immunol. 1994;24:26402645.[Medline] [Order article via Infotrieve]
61. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer J-L, Schroter M, Burns K, Mattmann C, Rimoldi D, French L, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190195.[Medline] [Order article via Infotrieve]
62.
Han DKM, Chaudhary PM, Wright ME, Friedman C,
Trask BJ, Riedel RT, Baskin DG, Schwartz SM, Hood L. MRIT, a novel
death-effector domain-containing protein, interacts with caspases and
BclXL and initiates cell death. Proc Natl
Acad Sci U S A. 1997;94:1133311338.
63.
Sata M, Walsh K. Endothelial cell
apoptosis induced by oxidized LDL is associated with the
downregulation of the cellular caspase inhibitor FLIP.
J Biol Chem. 1998;273:3310333106.
64.
Imanishi T, McBride J, Ho Q, OBrien KD,
Schwartz SM, Han DKM. Expression of cellular
FLICE-inhibitor protein in human coronary arteries
and in a rat vascular injury model. Am J Pathol. 2000;156:125137.
65.
Hewicker M, Trautwein G. Sequential study of
vasculitis in MRL mice. Lab Anim. 1987;21:335341.
66. Taniguchi Y, Ito MR, Mori S, Yonehara S, Nose M. Role of macrophages in the development of arteritis in MRL strains of mice with a deficit in Fas-mediated apoptosis. Clin Exp Immunol. 1996;106:2634.[Medline] [Order article via Infotrieve]
67. Sata M, Walsh K. Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels. J Mol Cell Cardiol. In press.
68.
Luo Z, Sata M, Nguyen T, Kaplan JM, Akita GY,
Walsh K. Adenovirus-mediated delivery of Fas ligand inhibits intimal
hyperplasia after balloon injury in immunologically primed animals.
Circulation. 1999;99:17761779.
This article has been cited by other articles:
![]() |
I. E. Dumitriu, E. T. Araguas, C. Baboonian, and J. C. Kaski CD4+CD28null T cells in coronary artery disease: when helpers become killers Cardiovasc Res, January 1, 2009; 81(1): 11 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Reddy, J. K. Vasir, S. K. Sahoo, T. K. Jain, M. M. Yallapu, and V. Labhasetwar Inhibition of Apoptosis Through Localized Delivery of Rapamycin-Loaded Nanoparticles Prevented Neointimal Hyperplasia and Reendothelialized Injured Artery Circ Cardiovasc Interv, December 1, 2008; 1(3): 209 - 216. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schober Chemokines in Vascular Dysfunction and Remodeling Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1950 - 1959. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kondo, Y. Tang, E. A. Scheef, N. Sheibani, and C. M. Sorenson Attenuation of retinal endothelial cell migration and capillary morphogenesis in the absence of bcl-2 Am J Physiol Cell Physiol, June 1, 2008; 294(6): C1521 - C1530. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Sedding, M. Homann, U. Seay, H. Tillmanns, K. T. Preissner, and R. C. Braun-Dullaeus Calpain counteracts mechanosensitive apoptosis of vascular smooth muscle cells in vitro and in vivo FASEB J, February 1, 2008; 22(2): 579 - 589. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Sanz-Gonzalez, L. Barquin, I. Garcia-Cao, M. Roque, J. M. Gonzalez, J. J. Fuster, M. T. Castells, J. M. Flores, M. Serrano, and V. Andres Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis Cardiovasc Res, September 1, 2007; 75(4): 803 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chen, L. Yang, and T. M. McIntyre Cytotoxic Phospholipid Oxidation Products: CELL DEATH FROM MITOCHONDRIAL DAMAGE AND THE INTRINSIC CASPASE CASCADE J. Biol. Chem., August 24, 2007; 282(34): 24842 - 24850. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aikawa The Balance of Power: The Law of Yin and Yang in Smooth Muscle Cell Fate: Is YY1 a Vascular Protector? Circ. Res., July 20, 2007; 101(2): 111 - 113. [Full Text] [PDF] |
||||
![]() |
A.-L. Levonen, M. Inkala, T. Heikura, S. Jauhiainen, H.-K. Jyrkkanen, E. Kansanen, K. Maatta, E. Romppanen, P. Turunen, J. Rutanen, et al. Nrf2 Gene Transfer Induces Antioxidant Enzymes and Suppresses Smooth Muscle Cell Growth In Vitro and Reduces Oxidative Stress in Rabbit Aorta In Vivo Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 741 - 747. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-H. Wang, S. Verma, I-C. Hsieh, A. Hung, T.-T. Cheng, S.-Y. Wang, Y.-C. Liu, W. L. Stanford, R. D. Weisel, R.-K. Li, et al. Stem Cell Factor Attenuates Vascular Smooth Muscle Apoptosis and Increases Intimal Hyperplasia After Vascular Injury Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 540 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Orlandi, A. Francesconi, M. Marcellini, A. Di Lascio, and L. G. Spagnoli Propionyl-L-carnitine Reduces Proliferation and Potentiates Bax-related Apoptosis of Aortic Intimal Smooth Muscle Cells by Modulating Nuclear Factor-{kappa}B Activity J. Biol. Chem., February 16, 2007; 282(7): 4932 - 4942. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Isobe, S. Tsimikas, J. Zhou, S. Fujimoto, M. Sarai, M. J. Branks, A. Fujimoto, L. Hofstra, C. P. Reutelingsperger, T. Murohara, et al. Noninvasive Imaging of Atherosclerotic Lesions in Apolipoprotein E-Deficient and Low-Density-Lipoprotein Receptor-Deficient Mice with Annexin A5 J. Nucl. Med., September 1, 2006; 47(9): 1497 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Brunt, K. K. Fenrich, G. Kiani, M. Yat Tse, S. C. Pang, C. A. Ward, and L. G. Melo Protection of Human Vascular Smooth Muscle Cells From H2O2-Induced Apoptosis Through Functional Codependence Between HO-1 and AKT Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2027 - 2034. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Martin-Ventura, V. Nicolas, X. Houard, L. M. Blanco-Colio, A. Leclercq, J. Egido, R. Vranckx, J.-B. Michel, and O. Meilhac Biological Significance of Decreased HSP27 in Human Atherosclerosis Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1337 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Pfrommer, W. Erl, and P. C. Weber Docosahexaenoic acid induces ciap1 mRNA and protects human endothelial cells from stress-induced apoptosis Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2178 - H2186. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lim, C. J. Jin, M. Kim, S. S. Chung, H. S. Park, I. K. Lee, C. T. Lee, Y. M. Cho, H. K. Lee, and K. S. Park PPAR{gamma} Gene Transfer Sustains Apoptosis, Inhibits Vascular Smooth Muscle Cell Proliferation, and Reduces Neointima Formation After Balloon Injury in Rats Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 808 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ono, T. Ichiki, H. Ohtsubo, K. Fukuyama, I. Imayama, Y. Hashiguchi, J. Sadoshima, and K. Sunagawa Critical Role of Mst1 in Vascular Remodeling After Injury Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1871 - 1876. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zernecke, A. Schober, I. Bot, P. von Hundelshausen, E. A. Liehn, B. Mopps, M. Mericskay, P. Gierschik, E. A. Biessen, and C. Weber SDF-1{alpha}/CXCR4 Axis Is Instrumental in Neointimal Hyperplasia and Recruitment of Smooth Muscle Progenitor Cells Circ. Res., April 15, 2005; 96(7): 784 - 791. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Ashton, G. St. J. Whitley, P. R. Dash, M. Wareing, I. P. Crocker, P. N. Baker, and J. E. Cartwright Uterine Spiral Artery Remodeling Involves Endothelial Apoptosis Induced by Extravillous Trophoblasts Through Fas/FasL Interactions Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 102 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wang, W. Sun, and X. Wang Intramuscular gene transfer of CGRP inhibits neointimal hyperplasia after balloon injury in the rat abdominal aorta Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1582 - H1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Rossi, N. Marziliano, P. A. Merlini, E. Bramucci, U. Canosi, G. Belli, D. Z. Parenti, P. M. Mannucci, and D. Ardissino Different Quantitative Apoptotic Traits in Coronary Atherosclerotic Plaques From Patients With Stable Angina Pectoris and Acute Coronary Syndromes Circulation, September 28, 2004; 110(13): 1767 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yang, K. Sato, T. Aprahamian, N. J. Brown, J. Hutcheson, A. Bialik, H. Perlman, and K. Walsh Endothelial Overexpression of Fas Ligand Decreases Atherosclerosis in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1466 - 1473. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nagata, R. Takeda, M. Sata, H. Satonaka, E. Suzuki, T. Nagano, and Y. Hirata AMP-Activated Protein Kinase Inhibits Angiotensin II-Stimulated Vascular Smooth Muscle Cell Proliferation Circulation, July 27, 2004; 110(4): 444 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Aprahamian, I. Rifkin, R. Bonegio, B. Hugel, J.-M. Freyssinet, K. Sato, J. J. Castellot Jr., and K. Walsh Impaired Clearance of Apoptotic Cells Promotes Synergy between Atherogenesis and Autoimmune Disease J. Exp. Med., April 19, 2004; 199(8): 1121 - 1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Skurk, H. Maatz, H.-S. Kim, J. Yang, M. R. Abid, W. C. Aird, and K. Walsh The Akt-regulated Forkhead Transcription Factor FOXO3a Controls Endothelial Cell Viability through Modulation of the Caspase-8 Inhibitor FLIP J. Biol. Chem., January 9, 2004; 279(2): 1513 - 1525. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-B. Michel Anoikis in the Cardiovascular System: Known and Unknown Extracellular Mediators Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2146 - 2154. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. C. Tung, G. Cui, K. Oshima, H. Laks, and L. Sen Balanced expression of mitochondrial apoptosis regulatory proteins correlates with long-term survival of cardiac allografts Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2832 - H2841. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tokunou, R. Shibata, H. Kai, T. Ichiki, T. Morisaki, K. Fukuyama, H. Ono, N. Iino, S. Masuda, H. Shimokawa, et al. Apoptosis Induced by Inhibition of Cyclic AMP Response Element-Binding Protein in Vascular Smooth Muscle Cells Circulation, September 9, 2003; 108(10): 1246 - 1252. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sata, K. Tanaka, N. Ishizaka, Y. Hirata, and R. Nagai Absence of p53 Leads to Accelerated Neointimal Hyperplasia After Vascular Injury Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1548 - 1552. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-W. Park, H.-M. Yang, S.-W. Youn, H.-J. Yang, I.-H. Chae, B.-H. Oh, M.-M. Lee, Y.-B. Park, Y.-S. Choi, H.-S. Kim, et al. Constitutively Active Glycogen Synthase Kinase-3{beta} Gene Transfer Sustains Apoptosis, Inhibits Proliferation of Vascular Smooth Muscle Cells, and Reduces Neointima Formation After Balloon Injury in Rats Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1364 - 1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Napoli, L. O. Lerman, F. de Nigris, J. Loscalzo, and L. J. Ignarro Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells J. Am. Coll. Cardiol., October 16, 2002; 40(8): 1515 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O. Laukkanen, A. Kivela, T. Rissanen, J. Rutanen, M. K. Karkkainen, O. Leppanen, J. H. Brasen, and S. Yla-Herttuala Adenovirus-Mediated Extracellular Superoxide Dismutase Gene Therapy Reduces Neointima Formation in Balloon-Denuded Rabbit Aorta Circulation, October 8, 2002; 106(15): 1999 - 2003. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kraemer Reduced Apoptosis and Increased Lesion Development in the Flow-Restricted Carotid Artery of p75NTR-Null Mutant Mice Circ. Res., September 20, 2002; 91(6): 494 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakajima, S. Schulte, K. J. Warrington, S. L. Kopecky, R. L. Frye, J. J. Goronzy, and C. M. Weyand T-Cell-Mediated Lysis of Endothelial Cells in Acute Coronary Syndromes Circulation, February 5, 2002; 105(5): 570 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Suhara, H.-S. Kim, L. A. Kirshenbaum, and K. Walsh Suppression of Akt Signaling Induces Fas Ligand Expression: Involvement of Caspase and Jun Kinase Activation in Akt-Mediated Fas Ligand Regulation Mol. Cell. Biol., January 15, 2002; 22(2): 680 - 691. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. P. Agema, J. W. Jukema, S. N. Pimstone, and J. J. P. Kastelein Genetic aspects of restenosis after percutaneous coronary interventions;towards more tailored therapy Eur. Heart J., November 2, 2001; 22(22): 2058 - 2074. [PDF] |
||||
![]() |
M. Sata, S. Sugiura, M. Yoshizumi, Y. Ouchi, Y. Hirata, and R. Nagai Acute and Chronic Smooth Muscle Cell Apoptosis After Mechanical Vascular Injury Can Occur Independently of the Fas-Death Pathway Arterioscler Thromb Vasc Biol, November 1, 2001; 21(11): 1733 - 1737. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Patterson, G. A. Stouffer, N. Madamanchi, and M. S. Runge New Tricks for Old Dogs : Nonthrombotic Effects of Thrombin in Vessel Wall Biology Circ. Res., May 25, 2001; 88(10): 987 - 997. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |